SCHEMBL13601817

SCHEMBL13601817

Cc1nc(C(=O)N(C)C(C)C(=O)O)c(O)c2ccc(Oc3ccccc3)cc12

nearest known ligand 0.59

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 14/20 0.59
THRA P10827 5/20 0.59
THRB P10828 5/20 0.59
BBOX1 O75936 1/20 0.59
SLC6A2 P23975 1/20 0.59
SLC6A3 Q01959 1/20 0.59
ASPH Q12797 1/20 0.59
KDM8 Q8N371 1/20 0.59
FTO Q9C0B1 1/20 0.59
EGLN2 Q96KS0 11/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13601814 0.92 EGLN1 (0.52) EGLN1THRATHRBBBOX1SLC6A2
SCHEMBL13601811 0.85 THRA (0.52) EGLN1THRATHRBBBOX1SLC6A2
SCHEMBL13601810 0.83 EGLN2 (0.58) EGLN1EGLN2
SCHEMBL29726486 0.82 EGLN1 (0.66) EGLN1THRATHRBBBOX1SLC6A2
SCHEMBL14672078 0.81 EGLN1 (0.71) EGLN1THRATHRBBBOX1SLC6A2
SCHEMBL2350847 0.80 EGLN1 (0.63) EGLN1THRATHRBBBOX1SLC6A2
SCHEMBL28618625 0.80 EGLN1 (0.63) EGLN1THRATHRBBBOX1SLC6A2
SCHEMBL523139 0.80 EGLN1 (0.69) EGLN1THRATHRBBBOX1SLC6A2
SCHEMBL523140 0.80 EGLN1 (0.69) EGLN1THRATHRBBBOX1SLC6A2
SCHEMBL16280563 0.79 EGLN1 (0.68) EGLN1THRATHRBBBOX1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7629357-B2 Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents FIBROGEN, INC. (US) 2009-12-08 US disclosed
US-7629357-B2 Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents FIBROGEN, INC. (US) 2009-12-08 US disclosed